Skip to main content
. 2022 Mar 27;14(4):720. doi: 10.3390/pharmaceutics14040720

Figure 3.

Figure 3

(a) Tumor size progression for 177Lu2O3-iPSMA, 177Lu2O3-iFAP, and 177Lu2O3 groups at different days of the treatment, without statistically significant difference (p > 0.05) between 177Lu2O3-iPSMA and 177Lu2O3-iFAP and with statistically significant difference (p < 0.05) of 177Lu2O3-iPSMA and 177Lu2O3-iFAP vs. 177Lu2O3 nanoparticles and the control group; (b) The mean radiation absorbed doses of 177Lu2O3-iPSMA, 177Lu2O3-iFAP, and 177Lu2O3 delivered to HCT116 tumors.